Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02510300 · ClinicalTrials.gov registry record
A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
A clinical trial, sponsored by Gilead Sciences.
- Terminated
- Registry status
- 461
- Enrollment target
NCT02510300 is a clinical trial that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 461 participants.
The verdict
NCT02510300 was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- 461 participants
- Enrollment target
Study Summary
This Registry will enroll adolescent and pediatric participants who received at least one Gilead Hepatitis C Virus (HCV) direct acting antiviral (DAA) while participating in a Gilead-sponsored chronic hepatitis C clinical trial. The primary objective of this Registry is to determine the long-term safety of anti-HCV regimens in the pediatric population. Secondary objectives of this Registry are to determine whether subsequent detection of HCV RNA in participants who relapse following sustained virologic response (SVR) represents the re-emergence of pre-existing virus, the development of resistance mutations, or whether it is due to re-infection, and to characterize resistance mutations and the persistence of resistance mutations in pediatric participants who did not achieve SVR. Once enrolled, participants will be followed for up to 5 years.
Interventions
- DRUG Sofosbuvir/Velpatasvir (SOF/VEL)
- DRUG Sofosbuvir (SOF)
- DRUG Ledipasvir/Sofosbuvir (LDV/SOF)
- DRUG Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 461 participants |
| Start Date | 2015-10-21 |
| Est. Completion | 2023-01-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02510300
The ClinicalTrials.gov registry entry for NCT02510300 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 461 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Sofosbuvir/Velpatasvir (SOF/VEL) is the first listed.
NCT02510300 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02510300 about?
NCT02510300 is a clinical study titled "A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials". This Registry will enroll adolescent and pediatric participants who received at least one Gilead Hepatitis C Virus (HCV) direct acting antiviral (DAA) while participating in a Gilead-sponsored chronic hepatitis C clinical trial. The primary objective of this Registry is to determine the long-term sa...
What is the current status of trial NCT02510300?
This trial is currently terminated. The enrollment target is 461 participants. The study started on 2015-10-21. Estimated completion is 2023-01-06.
What interventions are being tested in trial NCT02510300?
The interventions under investigation include: Sofosbuvir/Velpatasvir (SOF/VEL) (DRUG), Sofosbuvir (SOF) (DRUG), Ledipasvir/Sofosbuvir (LDV/SOF) (DRUG), Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) (DRUG).
Who is sponsoring clinical trial NCT02510300?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.